Market Overview

UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts

Share:
Related ACOR
Mid-Day Market Update: Headwaters Surges On Acquisition News; Cubic Shares Slide
Mid-Morning Market Update: Markets Open Higher; Symantec To Acquire Lifelock

Citigroup raised its rating on Acorda Therapeutics (NASDAQ: ACOR) from Neutral to Buy and raised its price target from $28 to $33.

Citigroup said, "We expect Ampyra to continue to grow fueled by modest market share gains and price increases. We project a 10% price increase in Q1:13 and 5% annually thereafter as there is still pricing power for the brand. This is overlooked by investors and should drive Ampyra's growth. We see limited downside to the stock as the stock is undervalued based on DCF esp. after its poor performance in 2012."

Acorda Therapeutics closed at $24.86 on Wednesday.

Latest Ratings for ACOR

DateFirmActionFromTo
Oct 2016Leerink SwannAssumesMarket Perform
Mar 2016Goldman SachsInitiates Coverage onNeutral
Jan 2016Aegis CapitalMaintainsBuy

View More Analyst Ratings for ACOR
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ACOR)

View Comments and Join the Discussion!